IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS

IN8BIO, INC.

All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.
One-year PFS/OS 100% vs historical controls (CIBMTR PFS 67.8%, OS 74.7%).
No cytokine release syndrome or neurotoxicity observed; manageable GvHD in line with historical data.
Patients median age 68, high-risk, including prior CAR-T failures; therapy well-tolerated.
Company to host conference call today at 8:30am ET to discuss data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.